Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Atopic Dermatitis | Emerging Therapies | Eucrisa (crisaborole) | US | Wave 2 | 2017

Login to access report north_east
Contact sales account_box

Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What is U.S. dermatologists’ awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
  • Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
  • What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?

Methodology: ~75 U.S. dermatologists complete a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Eucrisa

Key companies: Pfizer

Related reports: Atopic Dermatitis | Disease Landscape and Forecast | US/EU/Japan, Atopic Dermatitis | Unmet Need | US/EU, Atopic Dermatitis | Access and Reimbursement | US, Atopic Dermatitis | Access and Reimbursement | EU5, Atopic Dermatitis | Current Treatment | EU5

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
north_east
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
north_east
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east